Immuneering Corp. Class A (IMRX)

Immuneering's stock experienced a 19% jump in late December 2025. In March 2026, positive Phase 2a trial data for atebimetinib in pancreatic cancer led to gains of 7.03% on March 6 and 24% on March 5, with 64% overall survival at 12 months. The company announced FDA and EMA alignment on its Phase 3 MAPKeeper 301 trial design. Immuneering presented data at the AACR Annual Meeting and participated in the Needham Virtual Healthcare Conference. Updated Phase 2a data was presented at the ASCO Annual Meeting. The Q4 2025 earnings report and positive Phase 2a survival data contributed to a positive market reaction, and analysts maintained a "Buy" rating as of May 2026.

Immuneering Corp.'s products are not subject to traditional consumer demand seasonality, as demand is driven by clinical trial progress, regulatory approvals, and market adoption. However, historical stock data suggests September has the highest probability of positive returns, while January has the lowest.

Immuneering Corp. is a clinical-stage biopharmaceutical company focused on improving patient outcomes in oncologic and neurologic diseases through translational bioinformatics. The company utilizes its Disease Cancelling Technology platform for drug discovery and offers computational biology capabilities. Its major product candidates include atebimetinib, a dual-MEK inhibitor in Phase 3 clinical trial, and envometinib, an oral MEK inhibitor in Phase 1/2a clinical trial. The company also has multiple deep cyclic inhibitor discovery programs.

Immuneering Corp. is headquartered in Cambridge, Massachusetts, and operates research facilities within the United States.

Immuneering's brand reputation has been largely positive due to promising clinical trial data and a strong analyst outlook. Atebimetinib's encouraging survival data in Phase 2a trials for pancreatic cancer has bolstered its reputation. However, a public offering in September 2025, which led to dilution concerns, caused a temporary dip in investor confidence, though analysts continued to emphasize the underlying positive clinical data and long-term potential.

Immuneering Corp. has 95 institutional owners holding 32,140,577 shares as of May 4, 2026, including Fmr Llc, Sanofi, and Vanguard Group Inc. Benjamin J. Zeskind, the CEO, directly holds 5.0% of shares, and Peter Feinberg bought 20,000 shares in January 2026. Insiders hold approximately 14% of the company, and the general public holds a 34% stake.